The shares of National Aluminium Company (NALCO) and Torrent Pharmaceuticals recorded sharp gains on November 10 after their respective Q2 results announcements boosted investor confidence. Transformers and Rectifiers (TARIL) shares however tanked 20 percent to hit the lower circuit at Rs 313.55 apiece.
NALCO shares surged nearly 9 percent to trade at Rs 254.98 apiece, the highest level seen by the stock in 11 months. Torrent Pharmaceuticals jumped around 7 percent to hit a fresh 52-week high of Rs 3,830 apiece.
NALCO Q2 Results:
NALCO on November 7 reported a consolidated net profit of Rs 1,430 crore for Q2 FY26. This marks a 37% YoY rise from the Rs 1,046 crore net profit reported in Q2 FY25. The firm's revenue from operations meanwhile rose more than 7 percent YoY to Rs 4,292 crore.
Along with the Q2 results, the company also announced the first interim dividend of Rs 4 per equity share for the financial year 2026. The company has fixed November 14 as the record date to determine the eligibility of the shareholders set to receive the payment. The payment of the interim dividend shall be made on or before December 6 to all eligible shareholders, whose names appear in the Register of Members as on record date.
Torrent Pharma Q2 Results:
Torrent Pharma on November 7 reported a net profit of Rs 591 crore for Q2 FY26, marking a 30.5 percent YoY rise from the Rs 453 crore net profit reported in the corresponding quarter of the previous financial year. The firm’s revenue from operations meanwhile rose over 14 percent YoY to Rs 3,302 crore.
Jefferies kept a ‘Buy’ call on the stock, with a target price of Rs 4,300 per share. This implies an upside potential of more than 20 percent from the stock’s previous closing price.
The international brokerage said that the firm’s September quarter earnings beat estimates, driven by stronger US and Brazil sales. It added that Indian market continued to see market-beating growth while supply disruptions cause decline in Germany’s CC growth.
Jefferies raised its FY26–28 EBITDA estimates for Torrent Pharma by 3 percent
Nuvama also kept a ‘Buy’ call on the stock, with a target price of Rs 4,180 apiece. This implies an upside potential of more than 20 percent from the stock’s previous closing price.
The international brokerage said that the firm’s revenue and EBITDA beat consensus estimate by 3 percent each. EBITDA margin of 32.8 percent was in line with forecast.
Transformers and Rectifiers (India) Q2 Results:
Transformers and Rectifiers (India) on November 8 reported a consolidated net profit of Rs 33.91 crore for Q2 FY26, marking a 25 percent YoY decrease from the Rs 45.25 crore net profit reported in the same quarter of the previous financial year.
The firm’s revenue from operations meanwhile saw marginal decline to Rs 460 crore during the July-September quarter of the ongoing financial year. EBITDA stood at Rs 65 crore, while EBITDA margin reduced to 13.81 percent.
Additionally, World Bank has debarred the company from participating in its financed projects over alleged corruption and fraud related to a $486 million Nigeria power grid project.
Also read: Our LIVE blog on Q2 updates
Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
